Currency In USD
| Previous Close | 1.1 |
| Open | 1.13 |
| Day High | 1.14 |
| Day Low | 1.08 |
| 52-Week High | 2.21 |
| 52-Week Low | 0.75 |
| Volume | 137,031 |
| Average Volume | 499,100 |
| Market Cap | 16.08M |
| PE | -1.19 |
| EPS | -0.91 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 1.13 |
| Change | -0.02 |
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumesSUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the t
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
GlobeNewswire Inc.
Feb 10, 2026 2:15 PM GMT
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submissio
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the Ca